MedTrace Logo

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

NCT01999764 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-07-14

No results posted yet for this study

Summary

This is a Phase IIa proof-of-concept study to evaluate the effects of oral QLT091001 on adults with impaired dark adaptation.

Conditions

  • Impaired Dark Adaptation

Interventions

DRUG

QLT091001

QLT091001 administered orally at multiple time points.

OTHER

Placebo

Placebo is administered orally at multiple time points.

Sponsors & Collaborators

  • QLT Inc.

    lead INDUSTRY

Principal Investigators

  • Sushanta Mallick, Ph.D MBA · QLT Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01999764 on ClinicalTrials.gov